‘Drug maker Pfizer (PFE) said late
Tuesday that it will discontinue research on an experimental lung
cancer drug after side effects led to an unexpected number of deaths in
patients.
Pfizer said it was canceling enrollments
for Phase 3 clinical trials for the drug, which was known as
figitumumab. The compound was being used in treatment for a disease
known non-adenocarcionoma, nonsmall-cell lung cancer.
According to Pfizer, the committee
monitoring the clinical trials said in September it saw a
“apparent imbalance” in serious side effects when using the
drug, including fatalities.’
Book Mark it-> del.icio.us | Reddit | Slashdot | Digg | Facebook | Technorati | Google | StumbleUpon | Window Live | Tailrank | Furl | Netscape | Yahoo | BlinkList